Antagomir-17-5p Stops Growth of Neuroblastoma Resistant to Therapy
Author Information
Author(s): Fontana Laura, Fiori Micol E., Albini Sonia, Cifaldi Loredana, Giovinazzi Serena, Forloni Matteo, Boldrini Renata, Donfrancesco Alberto, Federici Valentina, Giacomini Patrizio, Peschle Cesare, Fruci Doriana
Primary Institution: Istituto Superiore di Sanità, Rome, Italy
Hypothesis
MYCN transactivates the miRNA 17-5p-92 cluster, which inhibits p21 and BIM translation, contributing to neuroblastoma progression.
Conclusion
Antagomir-17-5p treatment can abolish tumor growth in therapy-resistant neuroblastoma by upregulating p21 and BIM, leading to cell cycle arrest and apoptosis.
Supporting Evidence
- MYCN amplification is linked to aggressive neuroblastoma and treatment failure.
- Antagomir-17-5p treatment led to increased p21 and BIM levels.
- Knockdown of miR-17-5p resulted in decreased tumor growth in vivo.
- High levels of miR-17-5p were associated with poor prognosis in neuroblastoma patients.
Takeaway
Researchers found that a special treatment can stop the growth of a stubborn type of cancer in kids by helping the body’s natural defenses work better.
Methodology
The study involved in vitro and in vivo experiments using neuroblastoma cell lines and mouse models to assess the effects of antagomir-17-5p on tumor growth and gene expression.
Limitations
The study primarily focused on specific neuroblastoma cell lines and may not fully represent all cases of neuroblastoma.
Participant Demographics
The study involved human neuroblastoma cell lines and mouse models.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website